{'fraction_non_alphanumeric': 0.029411764705882353, 'fraction_numerical': 0.0196078431372549, 'mean_word_length': 6.197183098591549, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting histone deacetylases (HDACs) and Wee1 for treating high‐risk neuroblastoma

Despite advances in treatment regimens, patients with high‐risk neuroblastoma have long‐term survival rates of < 40%. Wee1 inhibition in combination with CHK1 inhibition has shown promising results in neuroblastoma cells. In addition, it has been demonstrated that panobinostat can downregulate CHK1. Therefore, combination of panobinostat and MK‐1775 may result in synergistic cytotoxicity against neuroblastoma cell lines.